William J. Rogers

William J. Rogers's AcademicInfluence.com Rankings

William J. Rogers

Philosophy

#12232

World Rank

#16952

Historical Rank

Logic

#9056

World Rank

#11421

Historical Rank

philosophy Degrees

Download Badge

Philosophy

William J. Rogers's Degrees

Doctorate Medicine Stanford University

Why Is William J. Rogers Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William J. Rogers's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. (2000) (1287)
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. (2006) (807)
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. (2006) (706)
Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. (2001) (508)
Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. (2008) (461)
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. (2014) (451)
Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. (2000) (426)
Clinical Importance of Obesity Versus the Metabolic Syndrome in Cardiovascular Risk in Women: A Report From the Women’s Ischemia Syndrome Evaluation (WISE) Study (2004) (422)
Prognosis in Women With Myocardial Ischemia in the Absence of Obstructive Coronary Disease: Results From the National Institutes of Health–National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE) (2004) (421)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study (2012) (402)
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. (2011) (365)
Azithromycin for the secondary prevention of coronary events. (2005) (359)
The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. (1999) (343)
The Economic Burden of Angina in Women With Suspected Ischemic Heart Disease: Results From the National Institutes of Health–National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (2006) (298)
Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial (2002) (292)
Single Nucleotide Polymorphisms in Multiple Novel Thrombospondin Genes May Be Associated With Familial Premature Myocardial Infarction (2001) (287)
Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). (2001) (279)
Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. (2003) (275)
Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. (2005) (262)
Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. (2004) (232)
The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). (2009) (216)
Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. (2003) (207)
Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of the Women's Ischemia Syndrome Evaluation (WISE) study. (1999) (194)
The value of estimated functional capacity in estimating outcome: results from the NHBLI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. (2006) (145)
Social Networks Are Associated With Lower Mortality Rates Among Women With Suspected Coronary Disease: The National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation Study (2004) (137)
Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes (2004) (135)
Mild Renal Insufficiency Is Associated With Angiographic Coronary Artery Disease in Women (2002) (119)
Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients (2003) (107)
Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: results from the National Heart, Lung, and Blood Institute Women's Ischemia Syndrome Evaluation Study. (2004) (106)
The impact of myocardial flow reserve on the detection of coronary artery disease by perfusion imaging methods: an NHLBI WISE study. (2003) (98)
Dobutamine stress echocardiography in women with chest pain. Pilot phase data from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). (1999) (98)
Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study. (2010) (95)
Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation (WISE) Study. (2006) (85)
Depression symptom severity and reported treatment history in the prediction of cardiac risk in women with suspected myocardial ischemia: The NHLBI-sponsored WISE study. (2006) (82)
Large brachial artery diameter is associated with angiographic coronary artery disease in women. (2002) (76)
Psychosocial Variables Are Associated With Atherosclerosis Risk Factors Among Women With Chest Pain: The WISE Study (2001) (66)
The effect of obesity on quality of life in patients with diabetes and coronary artery disease. (2010) (66)
Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. (2016) (62)
Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary artery disease (2003) (58)
Ten-Year Mortality in the WISE Study (Women’s Ischemia Syndrome Evaluation) (2017) (57)
Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. (2013) (56)
Depression Is Associated With Cardiac Symptoms, Mortality Risk, and Hospitalization Among Women With Suspected Coronary Disease: The NHLBI-Sponsored WISE Study (2006) (56)
Importance of socioeconomic status as a predictor of cardiovascular outcome and costs of care in women with suspected myocardial ischemia. Results from the National Institutes of Health, National Heart, Lung and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). (2008) (55)
Economic Outcomes of Treatment Strategies for Type 2 Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (2009) (53)
Diagnostic, prognostic, and cost assessment of coronary artery disease in women. (2001) (51)
Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized control trial (2003) (48)
Hostility Scores Are Associated With Increased Risk of Cardiovascular Events in Women Undergoing Coronary Angiography: A Report from the NHLBI-Sponsored WISE Study (2005) (47)
History of anxiety disorders is associated with a decreased likelihood of angiographic coronary artery disease in women with chest pain: the WISE study. (2001) (42)
Socioeconomic Status Variables Predict Cardiovascular Disease Risk Factors and Prospective Mortality Risk among Women with Chest Pain (2003) (41)
A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). (2010) (38)
Race and Prognosis After Myocardial Infarction Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial (1993) (37)
Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. (1994) (36)
Pulse Pressure and Coronary Atherosclerosis Progression in Postmenopausal Women (2005) (33)
Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATP III and IDF criteria? (2008) (31)
Relationships of Obesity and Fat Distribution With Atherothrombotic Risk Factors: Baseline Results From the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial (2010) (27)
Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. (2002) (27)
Sudden Cardiac Death in Women With Suspected Ischemic Heart Disease, Preserved Ejection Fraction, and No Obstructive Coronary Artery Disease: A Report From the Women's Ischemia Syndrome Evaluation Study (2017) (21)
Women's angiographic vitamin and estrogen trial: design and methods. (2002) (19)
Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease (2005) (19)
Validation of the accuracy of pretest and exercise test scores in women with a low prevalence of coronary disease: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. (2004) (19)
Effect of coronary angiography on use of lipid-lowering agents in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. For the WISE Investigators. (2000) (18)
Electrocardiogram abnormalities predict angiographic coronary artery disease in women with chest pain: Results from the nhlbi wise study (2002) (16)
Left Ventricular Energy Model Predicts Adverse Events in Women With Suspected Myocardial Ischemia: Results From The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. (2013) (15)
Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy (2014) (15)
Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease. (2005) (14)
From Telemedicine to E-Health: Uncovering New Frontiers of Biomedical Research, Clinical Applications & Public Health Services Delivery (2002) (12)
Association of genetic variants in the HDL receptor , SRB 1 , with abnormal lipids in women with coronary artery disease (2003) (10)
Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain (2004) (10)
Safety and effectiveness of combined low molecular weight heparin and glycoprotein IIb/IIIa inhibitors. (2002) (9)
Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. (2003) (8)
801-1 In women with symptoms of ischemic heart disease, global and regional myocardial perfusion status by magnetic resonance imaging better assigns risk: Results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) (2004) (7)
Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D). (2011) (7)
Phytoestrogens and coronary microvascular function in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE) Study. (2007) (7)
1172-76 Healthcare costs for cardiovascular disease in women with and without obstructive coronary disease: Results from the National Institutes of Health-National Heart, Lung, and Blood Institutes-Sponsored Women's Ischemia Syndrome evaluation (WISE) (2004) (5)
What is the optimal tool to define appropriate therapy: the randomized clinical trial, meta-analysis, or outcomes research? Commentary. (1994) (5)
Coronary angiography results have minimal impact on use of lipid-lowering agents in women: pilot phase data from WISE (1998) (5)
Relation Between Clinical, Angiographic and Ischemic Findings at Baseline and Ischemia-Related Adverse Outcomes at 1 Year in the Asymptomatic Cardiac Ischemia Pilot Study (2016) (4)
Improved diagnosis and prognosis using Decisions Informed by Combining Entities (DICE): results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). (2013) (4)
Phytoestrogen blood levels and adverse outcomes in women with suspected ischemic heart disease (2020) (4)
FIRST DosingClopidogrelBasedon CYP 2 C 19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease (2011) (4)
AMG 145, A Monoclonal Antibody Against PCSK9, Significantly Reduces Lipoprotein (a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LAPLACE-TIMI 57 Trial (2013) (4)
Aortic flow conditions predict ejection efficiency in the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). (2017) (3)
Use of bio-informatics assessment schema (BIAS) to improve diagnosis and prognosis of myocardial perfusion data: results from the NHLBI-sponsored women's ischemia syndrome evaluation (WISE). (2016) (3)
Even “WISE-R?”—an Update on the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (2020) (3)
819-3 Coronary vascular dysfunction is only partially predicted by traditional cardiovascular risk factors in women undergoing evaluation for suspected ischemia: Results from the National Heart, Lung, and Blood Institute WISE study (2004) (2)
Factors, Symptom Evaluation, and Gender-Optimized Diagnostic Strategies (WISE) Study: Part I: Gender Differences in Traditional and Novel Risk Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (2007) (2)
847-6 Serum inflammatory markers correlate with hemoglobin levels in women undergoing evaluation for suspected ischemia: Results from the national heart, lung, and blood institute WISE study (2004) (1)
Abstract 804: Sudden Cardiac Death and Severity of Obstructive Coronary Artery Disease: A Report From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study (2009) (1)
Abstract 4178: Cardiovascular Event-Free Survival in Post-Menopausal Women with Polycystic Ovary Syndrome: Results from the Women's Ischemia Syndrome Evaluation (2006) (1)
Decisions Informed by Computing Entities (DICE) to improve prognostic value of myocardial perfusion imaging: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study (2011) (1)
CONSTRICTION OF THE BRACHIAL ARTERY DURING BRACHIAL ARTERY REACTIVITY TESTING PREDICTS MAJOR ADVERSE CLINICAL OUTCOMES IN WOMEN WITH SUSPECTED MYOCARDIAL ISCHEMIA: THE NHLBI-SPONSORED WOMEN’S ISCHEMIA SYNDROME EVALUATION (WISE) STUDY (2010) (1)
Does expanded artificial intelligence improve the prognostic value of myocardial perfusion imaging? A report from the NHLBI-sponsored women's ischemia syndrome evaluation (WISE) (2013) (0)
Effect of postmenopausal hormone therapy on major adverse cardiac events after percutaneous coronary intervention: the HERS trial (2002) (0)
Inflammation is not associated with coronary microvascular dysfunction in women with chest pain (2003) (0)
Abstract 2450: A Randomized Controlled Trial of Low Dose Hormone Therapy on Myocardial Ischemia in Postmenopausal Women with No Obstructive Coronary Artery Disease:Results from the NHLBI-sponsored WISE (2007) (0)
Do hot flashes explain the protective association between HRT and CAD in women: the NHLBI-sponsored WISE study (2002) (0)
HRT modulates brachial artery diameter and flow-mediated dilation: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study (2002) (0)
Abstract 2842: CMR-Determined Regional Myocardial Perfusion Uptake Rate Predicts Events in Women Without Obstructive Coronary Artery Disease: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study (2006) (0)
PHYTOESTROGEN BLOOD LEVELS, MAJOR ADVERSE CARDIAC EVENTS AND ANGINA HOSPITALIZATION: A REPORT FROM THE WOMEN's ISCHEMIA SYNDROME EVALUATION (2020) (0)
and Macrovascular and Microvascular Coronary Disease Outcome With Regard to Gender-Based Pathophysiology of Atherosclerosis (WISE) Study: Part II: Gender Differences in Presentation, Diagnosis, and Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (2007) (0)
6 A CASE OF NON-ISCHEMIC CARDIOMYOPATHY ASSOCIATED WITH POLYGLANDULAR AUTOIMMUNE SYNDROME TYPE II (2005) (0)
DIET, ANGIOGRAPHIC CORONARY DISEASE, AND CARDIOVASCULAR OUTCOMES IN WOMEN (2022) (0)
Can a pre-exercise test score predict prognosis in women with a low prevalence of coronary disease? The National heart, lung, and blood institute- sponsored women's ischemia syndrome evaluation (WISE) study (2003) (0)
Relationship between serum amyloid A and coronary artery disease in women: The NHLBI-sponsored women's ischemia syndrome evaluation (WISE) study (2003) (0)
methodology and feasibility report The Women's Ischemia Syndrome Evaluation (WISE) Study: protocol design, (2007) (0)
1119-94 Reduced functional capacity in women is associated with impaired vascular function (2004) (0)
Mildly reduced creatinine clearance is associated with coronary artery disease in women: The NHLBI-sponsored WISE study (2003) (0)
Phytosetrogens have a potentially adverse effect on coronary vasodilator (endothelial independent) function in women with suspected ischemia: a report from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study (2002) (0)
Bio-informatics assessment schema (BIAS) to improve myocardial perfusion image diagnostic and prognostic value: the NHLBI-sponsored women's ischemia syndrome evaluation (WISE) study (2014) (0)
IS A NORMAL BODY MASS INDEX PROTECTIVE IN WOMEN WITH METABOLIC SYNDROME AND SUSPECTED MYOCARDIAL ISCHEMIA? (2020) (0)
Determinants of Brachial Artery Endothelial Function in Women: Pilot Phase Results From the WISE Clinical Centers (1998) (0)
Effectiveness of cardioprotective medication in women with suspected ischemic heart disease syndrome: the NHLBI-sponsored women's ischemia synrome evaluation (WISE) study (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William J. Rogers?

William J. Rogers is affiliated with the following schools: